Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.

Normalised earnings before interest, tax, depreciation and amortisation (EBITDA) from commercial pharmaceuticals grew 13% ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...